MedTrace Logo

Comparative Study of High-Efficacy Disease Modifying Treatment of Relapsing Multiple Sclerosis

NCT06159712 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2023-12-07

No results posted yet for this study

Summary

The goal of this prospective, multi-center, non-blinded, non-randomized, non-intervention clinical trial is to compare immunologic, virologic and epigenetic factors in patients with active multiple sclerosis in standard 2.line treatment with ocrelizumab, rituximab, ofatumumab or natalizumab in Region Midt, Denmark. It aims to answer how the immunologic, virologic and epigenetic response in these patients are compared to healthy controls, and analyze their treatment effect in relation to this response. Participants will get an extra blood sample, when they have their routine blood samples taken.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

OTHER

Blood samples

Extra blood samples

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • Gødstrup Hospital

    collaborator OTHER

  • Regionshospitalet Viborg, Skive

    collaborator OTHER

  • Sorbonne University

    collaborator OTHER

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Morten Stilund, MD · University of Aarhus

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-27
Primary Completion
2024-11-30
Completion
2025-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06159712 on ClinicalTrials.gov